AL-S Pharma Overview
- Year Founded
-
2016
- Status
-
Private
- Latest Deal Type
-
Early Stage VC
- Investors
-
3
AL-S Pharma General Information
Description
Developer of antibody therapeutics designed to slow disease progression in amyotrophic lateral sclerosis by targeting misfolded SOD1. The company offers a recombinant human antibody that selectively depletes toxic misfolded SOD1 while preserving normal protein function, enabling patients with ALS to reduce disease-driving mechanisms and improve clinical outcomes.
Contact Information
Website
www.al-spharma.comCorporate Office
- Care of Neurimmune AG
- Wagistrasse 18, Schlieren
- 8952 Zurich
- Switzerland
Corporate Office
- Care of Neurimmune AG
- Wagistrasse 18, Schlieren
- 8952 Zurich
- Switzerland
AL-S Pharma Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 3. Early Stage VC | 30-Jan-2018 | Completed | Product Development | |||
| 2. Early Stage VC | 07-Dec-2016 | Completed | Product Development | |||
| 1. University Spin-Out | 01-Jan-2016 | Completed | Startup |
AL-S Pharma Patents
AL-S Pharma Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| AU-2024262641-A1 | In vivo imaging of an als biomarker and means therefor | Pending | 24-Apr-2023 | ||
| AU-2024262641-A9 | In vivo imaging of an als biomarker and means therefor | Pending | 24-Apr-2023 | ||
| EP-4454666-A1 | In vivo imaging of an als biomarker and means therefor | Pending | 24-Apr-2023 | ||
| EP-4702057-A1 | In vivo imaging of an als biomarker and means therefor | Pending | 24-Apr-2023 | ||
| US-20260306683-A1 | In vivo imaging of an als biomarker and means therefor | Pending | 24-Apr-2023 | A61K51/1096 |
AL-S Pharma Investors (3)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Neurimmune | Corporation | Minority | ||
| TVM Capital Life Science | Venture Capital | Minority | ||
| University of Zürich | University |
AL-S Pharma FAQs
-
When was AL-S Pharma founded?
AL-S Pharma was founded in 2016.
-
Where is AL-S Pharma headquartered?
AL-S Pharma is headquartered in Zurich, Switzerland.
-
What industry is AL-S Pharma in?
AL-S Pharma’s primary industry is Drug Discovery.
-
Is AL-S Pharma a private or public company?
AL-S Pharma is a Private company.
-
What is AL-S Pharma’s current revenue?
The current revenue for AL-S Pharma is .
-
Who are AL-S Pharma’s investors?
Neurimmune, TVM Capital Life Science, and University of Zürich have invested in AL-S Pharma.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process